Evidence map›Paper›PMID 25657746›Full record

ArticleJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2014

The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (Thromboangiitis Obliterans).

Ali Akbar Beigi, Mohammad Ali Hoghoughi, Afrooz Eshaghian, Akbar Hassan Zade, Hassan Masoudpour

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pharmacological treatment for Buerger's disease.The Cochrane database of systematic reviews · 2020
    Pooled it
  2. Pharmacological treatment for Buerger's disease.The Cochrane database of systematic reviews · 2016
    Pooled it
  3. Review
  4. Article
  5. Article
  6. Hyperhomocysteinemia, low vitamin B12, and low folic acid: Are risk factors of cerebral vascular thrombosis in northwest Iran?Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ali Akbar BeigiDepartment of Vascular Surgery, Saint Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohammad Ali HoghoughiDepartment of Surgery, Saint Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Afrooz EshaghianDepartment of Head and Neck Surgery, Saint Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Akbar Hassan ZadeDepartment of Epidemiology and Biostatistics, Isfahan University of Medical Sciences, Isfahan, Iran.
Hassan MasoudpourMolecular Structure and Function, Research Institute, The Hospital for Sick Children, University of Toronto, Ontario, Canada.
Isfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe mechanism underlying Buerger's disease (BD) is still unknown. Recently, thrombophilic conditions predisposing to a hypercoagulable state have been hypothesized as triggers for BD. The aim of the study is to evaluate the prevalence of the hyperhomocysteinemia and level of the anticardiolipin antibodies, and the role of folic acid on the hyperhomocysteinemia and on the rate of the amputations in the patients with BD. MATERIALS AND

methodsIn an experimental placebo-controlled double-blinded study, between 2004 and 2010, thirty patients with BD were randomly assigned into two groups (14 patients in a drug group and 16 patients in the placebo group). Drug or placebo was administered, and they were followed in 2 and 6 months for homocysteine, Anticardiolipin antibodies and the risk of amputations.

resultsAt the beginning of the study homocysteine level was higher than normal in 19 patients (63%). There was a significant decrease in homocysteine level during 6 months in folic acid group (P < 0.001), but there was no change in the placebo group. None of our patients had elevated Anticardiolipin antibodies, and there was no change in the level of Anticardiolipin antibody during study. High level of homocysteine did not associate with more amputations during 6 months of study (P > 0.05).

conclusionThis study shows the hyperhomocysteinemia in BD, and the benefit of folic acid treatment in homocysteine lowering, but folic acid doesn't inhibit the risk of major and minor amputation during 6 months of follow-up. Longer follow-up may reveal the role of folic acid in these patients.

Indexed as

Anticardiolipin antibodiesBuerger's diseasefolic acidhyperhomocysteinemiathromboangiitis obliterans

Identifiers

PMID25657746
PMCPMC4310074
OpenAlexW173438471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.